Lawrence A. Kenyon

This profile gathers the share dealings of Lawrence A. Kenyon across 3 companies, led by PAR Pharmaceutical Companies, Inc., Outlook Therapeutics, Inc. and Alfacell Corp. Between 11 April 2007 and 14 August 2026, the trades on record add up to 38 filings.

Both buying and selling appear: 10 purchases worth €100k, against 22 sales worth €431k. The totals do not cover 1 filing with an undisclosed amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 5 share grants and 1 option exercise. 2026 to date brings 1 purchase and no sales.

A typical purchase (the median) is worth €7,963. 2 out of 3 purchases came within 30 days of a purchase by at least one other insider of the same company. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. Looking at 3 purchases old enough to measure, the stock rose over the following 90 days in 33% of cases; the median change was -64.4%. They describe history only and say nothing certain about the share price ahead.

The record was last updated on 14 August 2026 with an open-market purchase in Outlook Therapeutics, Inc. Publication is fast: at least half of the trades appear on SEC (Form 4) on the same day. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.